Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212122 | 1.00 | LMNA (0.33) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212295 | 1.00 | LMNA (0.33) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212154 | 1.00 | LMNA (0.33) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212314 | 1.00 | LMNA (0.33) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212133 | 0.89 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212419 | 0.89 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212310 | 0.89 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212385 | 0.89 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212570 | 0.88 | SMN1; SMN2 (0.31) | SMN1; SMN2CCR1 | |
| SCHEMBL35211727 | 0.88 | SMN1; SMN2 (0.31) | SMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | LMNA 1019/4885MAPK1 1919/4885SMN1; SMN2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.